Partner News: Artyc Launches Medstow Mini for Temperature Stable Blood Sample Collection and Delivery
Artyc PBC, a California-based cold chain startup, announced today the launch of Artyc’s Medstow Mini, a small battery-powered cooling container designed to transport medical goods through the supply chain.
SAN FRANCISCO, September 12th, 2023 – Artyc PBC, a California-based cold chain startup, announced today the launch of Artyc’s Medstow Mini, a small battery-powered cooling container designed to transport medical goods through the supply chain.
The Medstow Mini is a reusable active temperature stabilization and cooling container for shipping blood samples, blood vials, and cells collected within the home or clinical settings. The Medstow Mini can withstand varying ambient temperatures, prevent temperature excursions, and provide live data insights on location and temperature of samples via a user-friendly app.
Artyc entered a joint development program for the Medstow Mini with Tasso Inc., the leading provider of patient-centric clinical-grade blood collection solutions, to develop a logistics solution that supports the temperature-controlled delivery of high-quality decentralized blood testing solutions for the pharmaceutical industry. Leveraging Tasso’s end-to-end integrated logistics platform to support shipping, participant engagement and more, the Medstow Mini is designed to meet the needs of next-generation at-home sample collection and remote diagnostics to ensure both accuracy and regulatory compliance for customers.
“With the launch of the Medstow Mini, Artyc is taking a first step towards building a sustainable cold chain,” said Hannah Sieber, co-founder and CEO of Artyc. “The Medstow Mini allows our customers to increase healthcare access, reduce packaging waste, and slash cold chain emissions. In partnership with Tasso, we’re excited to offer a novel solution for shipments of at-home diagnostics.”
Historically, global supply chains have relied on cold chain infrastructure such as refrigerated trucks, cold rooms, and cold packs to keep products at stable temperatures. Yet, these transport systems and cooling technologies are energy, capital and labor intensive, often leading to a lack of tight temperature regulation and visibility and resulting in sample spoilage and excessive cold chain waste
“We are excited to see new technologies such as those from Artyc being developed to provide the highest level of control over blood sample logistics,” said Erwin Berthier, co-founder and CTO of Tasso. “Bringing diagnostics to the home will provide access to an essential component of healthcare to many underserved patients but will require new solutions that ensure the integrity of samples and an efficient, safe and seamless shipping process. Through our collaboration, Artyc is in a position to be a leader in this space.”
At every stage of transport, from source to destination, Artyc’s Medstow Mini ensures product integrity by controlling, monitoring and reporting temperatures. This feature set is crucial for medical logistics; when transporting blood, for example, specimens must be stored at refrigerated temperatures between +2 and +8 degrees Celsius at all times. Prolonged excursion outside of this temperature range will spoil the sample. By electrifying the cold chain, Artyc provides precision temperature control for days rather than hours and offers a solution that is both reusable and rechargeable for sustainable logistics.
The Artyc Medstow Mini is the first of a suite of products to be launched by Artyc that are purpose-built for the medical industry. The company is developing additional products for other industries which require a cold supply chain, such as food and agriculture.
Tasso and UBC Partner to Advance Decentralized Sample Collection and Analysis Solutions for Post-Approval Research
Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.
Seattle and Blue Bell, P.A., June 27, 2023 – Tasso, Inc., the leading provider of patient-centric clinical-grade blood collection solutions, and United BioSource LLC (UBC), a leading provider of evidence development solutions for the biopharmaceutical industry, today announced a partnership to provide more efficient, streamlined, and convenient sample collection and analysis options for post-approval research to improve study design and enable a better patient experience.
The new partnership will bring together Tasso’s devices for at-home, virtually painless clinical-grade blood sample collection and end-to-end collection and analysis solutions with UBC’s late-stage research expertise in evidence development and participant support services, including digital recruitment and engagement strategies, powerful real-world data infrastructure and rapid analytics software. Together, the two companies will offer a complete solution for biopharmaceutical companies seeking to improve participant retention and compliance, boost patient engagement, and enroll more diverse patient populations in decentralized post-approval studies.
Tasso and UBC have recently been awarded a late-stage biomarker monitoring study, with additional projects expected to follow.
“This collaboration combines UBC’s expertise in modernized study design and execution with our innovative offerings to create an unprecedented new solution for patient-centric, decentralized research,” said Ben Casavant, PhD, CEO and co-founder of Tasso, Inc. “Importantly, the collaboration will not only provide sponsors with the high-quality data they require but will also drive much-needed improvement in the patient experience and trial participant diversity.”
Research utilizing the joint offering will be powered by Tasso’s integrated solutions to streamline blood sample collection and analysis. After sponsors provide a list of samples needed, Tasso will handle shipping at-home blood collection kits directly to research participants, manage transport of samples to an analytical laboratory that has validated the specific test(s) needed, and communicate lab results back to the sponsor. The fully integrated Tasso Connect portal will ensure samples can be tracked with out-of-the-box functionality, and for seamless connectivity, partners can link with their own systems through Tasso’s API integration.
“With today’s rapidly evolving post-approval drug development requirements, there’s a real need to help sponsors efficiently, effectively, and safely execute and manage late-stage and real-world evidence generation research programs that meet regulatory and payer requirements and support their product commercialization objectives,” said Aaron Berger, Head of Evidence Development, UBC. “Our partnership with Tasso allows us to collectively provide flexible, integrated and innovative offerings that improve the patient experience and advance decentralized research methods.”
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
About UBC
United BioSource LLC (UBC) is the leading provider of evidence development solutions with an expertise in unifying evidence and access. UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Underpinned by our scientific expertise, data and analytics, and innovative technologies, we offer our customers flexible solutions generating the relevant real-world data necessary to make more informed decisions earlier, meet stakeholder requirements, and, ultimately, drive better patient outcomes. For additional information, visit www.ubc.com.
###
Media Contact:
Dina Schneider
Tasso, Inc.
(206) 822-4186 x1016
Amber Frasketi
UBC
(215) 588-8423
Partner News: Aptar Digital Health and Tasso Combine Capabilities to Facilitate Blood Sample Collection for Multiple Indications Including Chronic Conditions and Oncology
Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, and Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today entered into a collaboration to offer Aptar Digital Health end-users access to Tasso’s devices for blood collection. The collaboration will focus on improving patient care through a simplified and integrated experience, delivering clinical value to patients through a real-world deployment and increasing adoption of new technologies by patients, providers and pharmaceutical companies.
Crystal Lake, Illinois, June 13, 2023 – Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, and Tasso, Inc., the leading provider of patient-centric, clinical-grade blood collection solutions, today entered into a collaboration to offer Aptar Digital Health end-users access to Tasso’s devices for blood collection. The collaboration will focus on improving patient care through a simplified and integrated experience, delivering clinical value to patients through a real-world deployment and increasing adoption of new technologies by patients, providers and pharmaceutical companies.
“At Aptar Digital Health, we are committed to leveraging cutting-edge technology to enhance the patient experience,” said Sai Shankar, President of Aptar Digital Health. “The collaboration with Tasso to offer their technologies is a further step towards simplifying the patient journey.”
The Tasso blood collection devices will be available to patients included in Aptar Digital Health randomized-clinical trials and real-world studies, as well as to life science companies with whom Aptar Digital Health collaborates to develop digital health solutions, such as digital therapeutics, disease management platforms and digital PSPs.
Patients will have access to the Tasso+ and Tasso-M20 devices. The Tasso+ is a U.S. Food and Drug Administration (FDA) Class II 510(k)-cleared blood lancet that collects liquid whole blood samples, and the Tasso-M20, which is CE-marked, collects volumetrically-controlled dried whole blood samples from the patient for delivery to the lab. Onboarded patients will monitor their disease and symptoms through the digital health app provided by Aptar Digital Health and, when a blood test is required by the healthcare provider, samples will be collected with Tasso’s devices and sent for analysis.
The devices developed by Tasso collect clinical grade blood that can contain a large range of blood markers, from lipid and liver analytes, to antibodies to detect serostatus, and from specific select enzymes and proteins to certain cancer-specific antigens. This initiative will accelerate the use of a decentralized approach to blood collection and reduce the burden on patients related to laboratory testing.
“Our proprietary technology allows for easy, virtually-painless remote sample blood collection, creating an easier and more pleasant experience for patients and shifting how clinical research can be executed,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “We are dedicated to expanding access to patient-centric care, reducing barriers and supporting greater adoption of decentralized clinical trials. As part of that mission, we are pleased to collaborate with Aptar Digital Health, another leader working to transform healthcare, to offer a powerful combined solution for improving the clinical trial patient experience.”
About Aptar Digital Health
Aptar Pharma's Digital Health division is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health’s offering combines mobile and web apps, connected drug delivery systems, onboarding, training and advanced data analytics services to actively empower patients and create a positive treatment journey. Aptar is headquartered in Crystal Lake, Illinois and has 13,500 dedicated employees in 20 countries. For more information, visit www.aptar.com.
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
# # #
Media Contact:
Carolyn Penot
Aptar Pharma
+33 6 3736 7684
carolyn.penot@aptar.com
Partner News: CardioRenal receives FDA Breakthrough Device Designation for TENOR
CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), today announces that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
Breakthrough Device status will help advance the world’s first connected device to remotely monitor blood potassium levels in patients with severe chronic kidney disease
Grenoble, France, May 31, 2023 – CardioRenal, a pioneer in the remote treatment of patients with severe chronic kidney disease (CKD), today announces that its TENOR device has obtained Breakthrough Device Designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).
CardioRenal developed TENOR, a connected medical device that combines multiple innovative technologies to assist patients with chronic illnesses, including CKD, in measuring their blood potassium levels at home. Patients will collect blood for testing at home using Tasso+TM, a convenient, easy-to-use, virtually pain-free blood collection device with FDA 510(k) Class II medical device clearance. Doctors can then remotely access the measured data, enabling them to effectively control and normalize patient potassium levels.
“This designation is a tremendous recognition by the FDA of our R&D excellence. It will boost our efforts in bringing the TENOR device to the millions of patients who need it,” said Maurice Bérenger, CEO of CardioRenal. “We look forward to working closely with the FDA to start our clinical trials later this year.”
To qualify for this status, the equipment must feature breakthrough technologies, there must be no FDA-approved or cleared alternatives to the device, it must have significant advantages over existing approved or cleared alternatives, or its application must serve the best interests of patients.
“People are increasingly calling for at-home health solutions, and the partnership with CardioRenal is an exciting opportunity to again demonstrate the benefits to patient care,” said Ben Casavant, PhD, CEO and co-founder of Tasso, Inc., which makes the Tasso+ device. “We look forward to demonstrating that our blood collection device can be used in combination with the TENOR system to obtain a blood sample in a way that is convenient, addresses patient needs and meets FDA standards for potassium analysis. This fits perfectly in our mission to combine clinical excellence and patient-centric solutions.”
The FDA Breakthrough Devices Program helps patients receive timely access to innovative technologies that have the potential to provide more effective diagnosis or treatment for life-threatening or irreversibly debilitating diseases and conditions. As part of this program, the FDA will provide CardioRenal with priority review and interactive communication from its experts and senior managers, to assist the company on its path to commercialization in the US.
Globally, around 843 million people live with CKD. These patients frequently have fluctuating blood potassium levels, which exposes them to possible cardiac complications. These associated cardiovascular events account for up to 30% of deaths in patients with CKD.
About the FDA Breakthrough Devices Program
The goal of the Breakthrough Devices Program is to provide patients and health care providers with timely access to certain medical devices by speeding up their development, assessment and review, while preserving the statutory standards for premarket approval, 510(k) clearance and De Novo marketing authorization, consistent with the FDA’s mission to protect and promote public health.
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders.
For more information, please visit www.tassoinc.com
About CardioRenal
CardioRenal’s mission is to save CKD patient lives. The company’s solution, TENOR, is designed to allow patients to regain ownership of their health and improve their chronic disease management. Its breakthrough hardware technology and its AI based software platform enable doctors to optimize patient treatment through remote monitoring of key blood biomarkers.
www.cardio-renal.com
Q² Solutions Launches Innovative Self-Collection Safety Lab Panel in Collaboration With Tasso
Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
RESEARCH TRIANGLE PARK, N.C.– October 6, 2022 – Q² Solutions, a wholly owned subsidiary of IQVIA and a leading global clinical trial laboratory services organization, today announced the launch of the first self-collection safety lab panel for U.S. clinical trial participants by a leading global clinical trial laboratory.
Developed in collaboration with Tasso, Inc., a leader in clinical-grade blood collection solutions, this unique offering combines industry leading laboratory services, patient focused logistics and cutting-edge, self-collection technology.
Participants in clinical trials can now provide a blood specimen for lab testing in the comfort of their own home, without the need to visit an investigator site or have a healthcare professional visit them. The first test panel available through this collaboration is designed to help monitor liver function by measuring the levels of select enzymes and proteins in the blood. The panel includes tests for ALT (alanine transaminase), AST (aspartate aminotransferase), ALP (alkaline phosphatase), total bilirubin, direct bilirubin, total protein, and albumin.
“The global pandemic has accelerated the use of decentralized approaches in clinical trials,” said Brian O’Dwyer, CEO of Q² Solutions. “We at Q² Solutions are highly motivated to find ways to reduce patient burden related to laboratory testing, and I’m delighted that, through our collaboration with Tasso, we could make the self-collection liver panel a reality. Soon we will launch more than a dozen safety tests, and we are determined to continue to expand our catalog of tests available via the self-collection of blood.”
“We are thrilled to be working with a leader like Q² Solutions on this important initiative to make laboratory testing truly patient-centric,” said Erwin Berthier, PhD, CTO and Co-Founder of Tasso. “Our clinical-grade remote sampling technology enables decentralized laboratory testing without sacrificing sample quality, a key hurdle that home testing has faced in the past. Together, Q² Solutions and Tasso are developing important solutions that make clinical trials better for both patients and sponsors.”
This self-collection liver panel was developed with trial participants at the heart of the design. The offering includes easy to use at-home self-collection kits with instructions and videos, a methodology for direct-to-patient delivery, as well as simplified specimen processing and shipping requirements.
About Q² Solutions
Q² Solutions is a leading global clinical trial laboratory services organization that provides comprehensive testing, project management, supply chain, biorepository, biospecimen, and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients. We provide scientific expertise and innovative solutions for ADME, bioanalytical, genomics, vaccines, and central laboratory services, including flow cytometry, anatomic pathology, immunoassay, molecular, companion diagnostics and translational science, with meticulous regional and global clinical trial implementation support and high-quality data delivery. At Q² Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients and caregivers around the world into the help they need. To learn more, visit www.Q²labsolutions.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About Tasso
Trusted diagnostics made easy. Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
Contacts
Nick Childs, IQVIA Investor Relations
Nchilds@us.imshealth.com
+1.973.316.3828
Trent Brown, IQVIA Media Relations
trent.brown@iqvia.com
+1.919.780.3221
Catapult Health and Tasso Join Forces to Create Convenient, Patient-Centric Preventive Care Solution for Fortune 500 Employers and National Health Plans
Catapult Health, a virtual preventive care provider serving 3,500 employers with over 2 million covered lives, and Tasso Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced a collaboration that will simplify home-based preventive care for employees and their families. Effective October 5th, Catapult will start offering the Tasso+™ device as part of its VirtualCheckup, an innovative at-home annual wellness checkup that combines simple and virtually painless testing with face-to-face clinical video consultations.
At-home VirtualCheckup wellness exam to feature Tasso’s clinical-grade, self-sampling blood collection device
DALLAS and SEATTLE – Sept. 28, 2022 – Catapult Health, a virtual preventive care provider serving 3,500 employers with over 2 million covered lives, and Tasso Inc., the leading provider of convenient, clinical-grade blood collection solutions, today announced a collaboration that will simplify home-based preventive care for employees and their families. Effective October 5th, Catapult will start offering the Tasso+™ device as part of its VirtualCheckup, an innovative at-home annual wellness checkup that combines simple and virtually painless testing with face-to-face clinical video consultations. VirtualCheckup is already a covered benefit for hundreds of America’s largest corporations and major national health plans, including BlueCross and BlueShield.
“Tasso’s innovative blood collection device is a perfect addition to our VirtualCheckup kit because it allows individuals to easily collect their own blood sample at home, virtually pain-free and without the traditional finger stick,” said David Michel, CEO of Catapult Health. “Together, we will transform the annual wellness exam by driving mass adoption of our VirtualCheckup, a solution designed to identify and address health risks for costly chronic conditions including depression, hypertension, diabetes and heart disease, all before they turn into adverse health events.”
Each VirtualCheckup home kit will include the Tasso+ device, a blood pressure monitor, and a measuring tape. Following simple step-by-step instructions, the recipient sends a small blood sample, two blood pressure readings, and a few physical measurements to Catapult’s laboratory in Dallas. A few days later, the participant meets via secure video with a board-certified Catapult nurse practitioner who assesses personal and family health history, reviews medication compliance, screens for depression, discusses test results, creates a personal action plan, and refers the individual into health improvement programs offered by their employer or health plan.
Earlier this month, Tasso announced that the U.S. Food and Drug Administration (FDA) has cleared its Tasso+ lancet as a Class II medical device. The clearance allows the company to market and sell the device to more pharmaceutical companies, healthcare organizations, and academic institutions across the country, expanding access to a simple and virtually painless blood collection experience. For more information on the Tasso+ device-based solutions with Class II clearance, please visit www.tassoinc.com/contact.
“Today’s surging demand for virtual patient care further highlights the shortcomings of the painful, inconvenient, and inconsistent in-person blood draw procedure, which has been the standard of care for more than 60 years,” said Ben Casavant, PhD, CEO and cofounder of Tasso. “We are proud to partner with Catapult Health to improve preventive care by making the annual wellness exam a faster, easier, and more convenient experience for individuals across the country.”
Catapult Health is hosting a live-stream launch event featuring its new VirtualCheckup solution, the Tasso+ device, and the CEOs of each company at 1pm CST on Wednesday, October 5th. To register, visit www.CatapultHealth.com/live.
About Catapult Health
Catapult Health is the leading provider of virtual preventive care in America. With 3,500 employer customers and over 2 million covered lives, Catapult has revolutionized the annual preventive exam with its VirtualCheckup. Catapult’s solution targets health risks that lead to depression, hypertension, diabetes, and heart disease, and a recent third-party actuarial analysis of 416,000 patient records over 3 years revealed potential savings of $2.19 for every $1 invested. For more information, please visit www.catapulthealth.com.
VirtualCheckup is a registered trademark of Catapult Health.
About Tasso
Trusted diagnostics made easy. Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
Tasso, the Tasso logo, and Tasso+ are trademarks of Tasso, Inc.
Media Contacts
Tasso
Dina Schneider
(206) 822-4186 x1016
Catapult Health
Lee Dukes
(214) 906-7035
Vault Health and Tasso Partner for Expansion of Patient-Centric At-Home Diagnostics
Vault Health, an innovative healthcare company bringing virtual care to millions, today announced a partnership with Tasso, Inc., a leader in simple clinical grade blood collection technology, to integrate Tasso products and logistics into Vault’s turnkey service offering. The new partnership will enable an improved, virtually painless sample collection experience for Vault customers.
Partnership pairs Tasso’s signature blood collection devices with Vault’s turnkey, modular service offering for clinical development and home health
NEW YORK – February 1, 2022 – Vault Health, an innovative healthcare company bringing virtual care to millions, today announced a partnership with Tasso, Inc., a leader in simple clinical grade blood collection technology, to integrate Tasso products and logistics into Vault’s turnkey service offering. The new partnership will enable an improved, virtually painless sample collection experience for Vault customers.
Vault offers a range of services, including remote diagnostics, where samples can be collected without visiting a clinic. Through a partnership with Tasso, the company will make blood draws easier and more efficient by enabling patients to quickly and easily collect their own blood at home. In addition to remote diagnostics, Vault also provides telehealth and at-home based care and manages decentralized clinical trials, which are facilitated through high quality remote sample collection, such as that which Tasso provides.
“We’re obsessed with the experience of our patients and customers,” said Jason Feldman, CEO and Co-Founder of Vault Health. “That means making clinical research and clinical care more accessible to more people. Our medical staff and the technology platform they use relies on innovative medical devices like those developed by Tasso, in order to bring more care directly to people’s homes. We’re thrilled this partnership accelerates our ability to break down barriers to patient care, recruitment, participation, and retention of clinical research participants.”
Tasso’s signature blood collection products and logistics are currently in use worldwide for a variety of healthcare, pharma, and research applications. The devices enable virtually painless collection of clinical grade blood at a convenient time and location, elevating the traditional home testing experience.
“More than ever, there is a need to bring convenient health monitoring and care into the home,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Tasso’s simple, virtually painless blood collection devices bridge the gap between patient convenience and high-quality care. We are excited to partner with an industry leader like Vault Health to expand access to patient-centric clinical diagnostics.”
About Vault
Vault accelerates better health outcomes through faster diagnosis, innovative clinical research, and digital-first care delivery. Vault delivers care to patients on their terms, virtually or physically, by leveraging its national clinician network and data-driven tech platform to power its offerings. Vault has been a trusted leader in the fight against COVID-19, bringing the first FDA-authorized at-home PCR test to market. Since the start of the pandemic, Vault has delivered more than 12 million COVID-19 tests to consumers, employers, public health agencies, and school systems.
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
Media Contacts
Vault:
Kate Brickman
(815) 343-9299
Tasso:
Dina Schneider
(206) 822-4186 x1016
InnoVero and Tasso Partner to Provide Non-Invasive, Athlete-Centric Solutions for Anti-Doping Testing
InnoVero LLC, maker of the innovative SAFESystem™ sample collection kit currently revolutionizing global anti-doping practices, today announced a partnership with Tasso, Inc. to become the exclusive worldwide distributor for Tasso blood collection devices for the anti-doping marketplace. The partnership will accelerate global efforts to expand consistent non-invasive anti-doping testing.
Security Kit will ensure WADA compliance for Dried Blood Spot Testing for Doping Control and improve the athlete testing experience
COLORADO SPRINGS, CO – October 19, 2021 : InnoVero LLC, maker of the innovative SAFESystem™ sample collection kit currently revolutionizing global anti-doping practices, today announced a partnership with Tasso, Inc. to become the exclusive worldwide distributor for Tasso blood collection devices for the anti-doping marketplace. The partnership will accelerate global efforts to expand consistent non-invasive anti-doping testing.
In May 2021, the World Anti-Doping Agency (WADA) approved its first technical document on dried blood spot (DBS) testing for doping control, designed to harmonize testing requirements and procedures. The InnoVero-Tasso partnership will ensure that all collection protocols are followed accurately and consistently, through the development of a unique security kit that utilizes non-invasive DBS sample collection, in making these testing assets available to global anti-doping stakeholders.
“This partnership signals a pivotal moment in reducing the invasive blood collection procedures athletes often associate with sample collection, another prime example of the innovation InnoVero is bringing to global anti-doping stakeholders,” said Gabe Baida, Executive Director for InnoVero. “Athletes have asked for alternatives to blood draws, while anti-doping organizations have struggled with alternative options that promote security and efficiency along with athlete safety. The InnoVero-Tasso partnership signals a breakthrough opportunity in sample collection procedures, while keeping athlete needs at the forefront in minimizing the invasiveness.”
Tasso enables on-demand at-home blood collection for patients and athletes with an easy and virtually painless remote sample collection technology. The current portfolio of Tasso devices includes the Tasso-M20 for DBS testing, as well as the Tasso+ and Tasso-SST for liquid blood sample collection. Tasso devices are an alternative to traditional invasive and painful venipuncture blood draws, improving the athlete testing experience while still delivering clinical grade blood for analysis.
“Our partnership with InnoVero is an exciting step toward industry-wide acceptance of athlete-centric testing methods,” said Ben Casavant, CEO & Co-Founder of Tasso. “The combination of a virtually painless experience that can be done anywhere simplifies testing for athletes, no matter where their training regimens and competitions take them. We are pleased to be partnering with InnoVero to improve anti-doping testing for athletes worldwide.”
About InnoVero
InnoVero provides innovation and integrity to the global anti-doping community, through solutions designed to secure global athlete trust. InnoVero’s SAFESystem™ sample collection kit serves clients globally, with more than 50,000 kits produced and used by anti-doping organizations, located in Africa, Asia, Europe and Russia, as well by the United States Anti-Doping Agency, UFC and MLB. The SAFESystem™ features revolutionary security mechanisms that ensure its sample collection bottles are secure, athlete-friendly and tamper-evident, among a suite of features designed to provide seamless and efficient use by athletes, doping control officers and laboratories. For more information about InnoVero, please visit www.innoveroglobal.com
About Tasso
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable users to self-collect blood at home with a virtually painless, no-training-required process. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants from the Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, and the National Institutes of Health, by investments from Hambrecht Ducera Growth Ventures, Merck Global Health Innovation Fund, Foresite Capital, Vertical Venture Partners, Techstars, and Cedars Sinai, and by co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
CONTACTS:
InnoVero
Brad Horn
InnoVero
bhorn@innoveroglobal.com
(512) 636-3831
Tasso
Dina Schneider
Tasso, Inc.
media@tassoinc.com
(206) 822-4186 x1016